Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

Meisner, Eleanor; Rollins, Rebecca; Ensor, Joe; Moran, Amber; Woodward, A M; Ahn, Eugene; Lynch, Cynthia A.; Citrin, Dennis L.; Hansra, Damien Mikael; Aithal, Sramila; Ninan, Mary J.; Nixon, Daniel W.; Zook, S.; Ali, Siraj M.; Markman, Maurie; Álvarez, Ricardo H.

doi:10.1200/jco.2018.36.15_suppl.1074

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

Cited by 2 publications

References 0 publications

Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy

Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer

Contact Info

Product

Resources

About